Compositions and Methods for Treatment of Glaucoma
AssigneeEye Therapies LLC
InventorGerald Horn
Life of this patent
Estimating the term…
Abstract
The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine.
Claims24
A pharmaceutical composition for ophthalmic use comprising an active agent, water, a viscosity enhancing agent, and a gelling agent, wherein complex viscosity of said pharmaceutical composition increases during interblink low shear conditions to at least about 20 times a minimum complex viscosity of said composition when measured under high shear conditions of each blink.
A pharmaceutical composition comprising
- i. an α-2 adrenergic receptor agonist at a concentration from between about 0.0125% to about 0.125% weight by volume, wherein said α-2 adrenergic receptor has a Log P value of 2.0 or greater and has a binding affinity of 950 fold or greater for α-2 over α-1 adrenergic receptors;
- ii. a hypotonic salt or sterile water;
- iii. a poloxamer at a concentration of between about 2% and about 12% weight by volume;
- and
- iv. a viscosity enhancer,
- wherein said pharmaceutical composition has a viscosity of between 25 and 500 cps, and
- wherein said pharmaceutical composition is effective for the treatment of glaucoma in a patient in need thereof.
A pharmaceutical composition comprising:
- i. dexmedetomidine at a concentration from between 0.025% and about 1.25% weight by volume;
- ii. a poloxamer at a concentration of between about 2% and about 12% weight by volume;
- and
- iii. carboxymethyl cellulose (CMC) at about 0.5% to about 1%
- wherein said pharmaceutical composition is effective for the treatment of glaucoma in a patient in need thereof.
A pharmaceutical vehicle for a topical drug delivery, wherein said vehicle comprises:
- i. a hypotonic salt or sterile water;
- ii. a poloxamer at a concentration of 12% weight by volume or less;
- iii. a viscosity enhancer, and
- iv. an active agent
- wherein said pharmaceutical composition has a viscosity of between 25 and 500 cps.
An artificial tear solution comprising:
- a hypotonic salt or sterile water;
- ii. a poloxamer at a concentration of 12% weight by volume or less;
- and
- iii. a viscosity enhancer, and
- wherein said artificial tear solution has a viscosity of between 25 and 500 cps.
Dependencies are inferred from the claim text.